The clinical milestone is incremental and non-catalytic until actual data readout. The dominant near-term factor is the S-3 overhang and going concern warning filed yesterday — monitor for any pricing or takedown announcement under the shelf, which would crystallize dilution. The IgAN data by year-end 2026 is the next binary catalyst.
Price Chart
Executive Summary
Jasper Therapeutics announced completion of enrollment in the IgAN cohort of its Phase 2 basket study for vensobafusp alfa, with initial data expected by year-end 2026, and accelerated initiation of an FSGS cohort with first patient dosing expected in Q1 2027. The press release contains no financial data, no regulatory decision, and no material change in the company's risk profile. The cross-filing S-3 shelf registration filed yesterday (registering ~284M shares, ~8.5x current outstanding) creates massive dilution overhang and a going concern warning, which dominates the standalone clinical milestone.
Key Facts
- Completed enrollment of 18 IgAN patients in Phase 2 basket study of vensobafusp alfa (KP104)
- Initial interim data from IgAN cohort expected by year-end 2026
- Expansion cohort in FSGS initiated; first patient dosing anticipated Q1 2027
- S-3 shelf filed 2026-10-14 registers up to 284,013,011 shares for resale (~8.5x current 33.3M outstanding), with going concern warning and $320.6M accumulated deficit
- No financial results, guidance, or regulatory decisions provided in this press release
Financial Impact
No financial data in press release; S-3 cross-filing implies massive potential dilution (~8.5x current shares) and going concern risk with $320.6M accumulated deficit
Risk Factors
- Massive dilution risk from S-3 shelf registration (~284M shares, ~8.5x current outstanding)
- Going concern warning with $320.6M accumulated deficit and active need for additional capital
- Clinical-stage company with no approved products; vensobafusp alfa is investigational
- Interim data from small 18-patient cohort may not be predictive of later-stage results
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381578 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5050 (−0.98%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5050 (+1.02%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5050 (−5.09%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5050 (+5.08%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5050 (+5.09%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5050 (+17.09%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5050 (−36.08%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5050 (−19.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers